Difference between revisions of "Hepatitis B vaccine"
| Line 1: | Line 1: | ||
| − | The Hepatitis B vaccine | + | The Hepatitis B vaccine is a recombinant (non-living) vaccine used to prevent infection with the [Hepatitis B virus]. Most school age children, health care workers, and others who might be exposed to infectious bodily fluids are recommended or required to become vaccinated. |
| − | |||
'''Recombinant hepatitis B vaccine and the risk of multiple sclerosis''' | '''Recombinant hepatitis B vaccine and the risk of multiple sclerosis''' | ||
<br>A prospective study<ref>http://www.neurology.org/cgi/content/abstract/63/5/838</ref> | <br>A prospective study<ref>http://www.neurology.org/cgi/content/abstract/63/5/838</ref> | ||
Revision as of 21:13, April 4, 2007
The Hepatitis B vaccine is a recombinant (non-living) vaccine used to prevent infection with the [Hepatitis B virus]. Most school age children, health care workers, and others who might be exposed to infectious bodily fluids are recommended or required to become vaccinated.
Recombinant hepatitis B vaccine and the risk of multiple sclerosis
A prospective study[1]
Miguel A. Hernán, MD, DrPH, Susan S. Jick, DSc, Michael J. Olek, DO and Hershel Jick, MD
From the Department of Epidemiology (Dr. Hernán), Harvard School of Public Health, Boston; Boston Collaborative Drug Surveillance Program (Drs. Susan S. Jick and Hershel Jick), Boston University, Lexington, MA; and Department of Neurology (Dr. Olek), College of Medicine, University of California, Irvine.
Background: A potential link between the recombinant hepatitis B vaccine and an increased risk of multiple sclerosis (MS) has been evaluated in several studies, but some of them have substantial methodologic limitations.
Methods: The authors conducted a nested case-control study within the General Practice Research Database (GPRD) in the United Kingdom. ...
Results: The analyses include 163 cases of MS and 1,604 controls. The OR of MS for vaccination within 3 years before the index date compared to no vaccination was 3.1 (95% CI 1.5, 6.3). No increased risk of MS was associated with tetanus and influenza vaccinations.
Conclusions: These findings are consistent with the hypothesis that immunization with the recombinant hepatitis B vaccine is associated with an increased risk of MS, and challenge the idea that the relation between hepatitis B vaccination and risk of MS is well understood.
References: